Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Frontiers in endocrinology（2023）
摘要
ClinicalTrials.gov, identifier NCT02180217.
更多查看译文
关键词
Cushing's disease, osilodrostat, hypercortisolism, 11 & beta,-hydroxylase, long-term treatment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要